On the public citation graph

Prevalence of Drug Resistance Associated Substitutions in Hepatitis C-Infected Patients Whose WHO-Recommended Direct Acting Agents for Initial Treatment and Retreatment Fails: A Systematic Review and Meta-Analysis

https://doi.org/10.2139/ssrn.4613660
0 signed · 28 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/hep.27259openalex-extracted
Global distribution and prevalence of hepatitis C virus genotypes
inferredcites →https://doi.org/10.1002/hep.27726openalex-extracted
All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study
inferredcites →https://doi.org/10.1002/hep.30225openalex-extracted
Frequent Antiviral Treatment Failures in Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r
inferredcites →https://doi.org/10.1002/hep4.1060openalex-extracted
The emergence of NS5B resistance associated substitution S282T after sofosbuvir‐based treatment
inferredcites →https://doi.org/10.1016/j.ijantimicag.2019.07.005openalex-extracted
Efficacy and safety of glecaprevir/pibrentasvir for chronic hepatitis C virus genotypes 1–6 infection: A systematic review and meta-analysis
inferredcites →https://doi.org/10.1016/j.jhep.2016.09.001openalex-extracted
EASL Recommendations on Treatment of Hepatitis C 2016
inferredcites →https://doi.org/10.1016/j.jhep.2017.06.035openalex-extracted
Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries
inferredcites →https://doi.org/10.1016/j.jhep.2017.11.032openalex-extracted
Resistance analysis in patients with genotype 1–6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies
inferredcites →https://doi.org/10.1016/j.jhep.2019.07.025openalex-extracted
Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C
inferredcites →https://doi.org/10.1016/j.jhep.2019.10.017openalex-extracted
Is resistance to direct-acting antivirals in sub-Saharan Africa a threat to HCV elimination? Recommendations for action
inferredcites →https://doi.org/10.1016/j.jhep.2020.05.029openalex-extracted
Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia
inferredcites →https://doi.org/10.1016/j.jhep.2020.08.018openalex-extracted
EASL recommendations on treatment of hepatitis C: Final update of the series☆
inferredcites →https://doi.org/10.1016/j.jhep.2021.04.045openalex-extracted
Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens
inferredcites →https://doi.org/10.1016/j.jhepr.2022.100462openalex-extracted
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
inferredcites →https://doi.org/10.1038/nbt0114-3openalex-extracted
FDA approvals usher in the post-interferon era in HCV
inferredcites →https://doi.org/10.1053/j.gastro.2016.04.003openalex-extracted
Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens
inferredcites →https://doi.org/10.1093/cid/ciu697openalex-extracted
Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials
inferredcites →https://doi.org/10.1093/cid/ciy585openalex-extracted
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
inferredcites →https://doi.org/10.1093/infdis/jiab110openalex-extracted
Real-World Outcomes of Direct-Acting Antiviral Treatment and Retreatment in United Kingdom–Based Patients Infected With Hepatitis C Virus Genotypes/Subtypes Endemic in Africa
inferredcites →https://doi.org/10.1097/xeb.0000000000000054openalex-extracted
Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data
inferredcites →https://doi.org/10.1128/aac.01249-18openalex-extracted
Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials
inferredcites →https://doi.org/10.1186/2049-3258-72-39openalex-extracted
Metaprop: a Stata command to perform meta-analysis of binomial data
inferredcites →https://doi.org/10.21037/aob.2018.10.05openalex-extracted
Evaluating “treatment as prevention” on the road to hepatitis C virus elimination
inferredcites →https://doi.org/10.3390/v13081580openalex-extracted
SHARED: An International Collaboration to Unravel Hepatitis C Resistance
inferredcites →https://doi.org/10.3390/v15071489openalex-extracted
Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis
inferredcites →https://doi.org/10.3851/imp3181openalex-extracted
Long-Term Persistence of HCV NS5A Resistance-Associated Substitutions after Treatment with the HCV NS5A Inhibitor, Ledipasvir, without Sofosbuvir
inferredcites →https://doi.org/10.3851/imp3253openalex-extracted
Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infection
inferredcites →https://doi.org/10.7326/0003-4819-151-4-200908180-00135openalex-extracted
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.